{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:00:43Z","timestamp":1788778843425,"version":"build-2803163510"},"reference-count":27,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Treatment-free remission (TFR) is an opportunity for patients with chronic myeloid leukemia (CML). Reported cumulative incidence curves of molecular recurrence (MRec) arbor a 2-phase shape with mainly early events, but also some late events (late MRec [LMRec]). Having discontinued our first patient in 2004, we have access to a prolonged follow-up, enabling us to characterize these late events. Over 15 years, 128 patients from our institution were registered in the Stop Imatinib (STIM; A Study for Tyrosine Kinase Inhibitors Discontinuation [A-STIM]) trial. MRec was defined by the loss of major molecular response (BCR-ABL1IS &amp;gt;0.1%). At the first TFR attempt, patients had been taking a tyrosine kinase inhibitor for a median of 7.1 years and in BCR-ABL1IS \u22640.01% (MR4) for a median of 4 years. The median follow-up of patients in TFR was 6.5 years. The TFR rate was estimated to be 45.6% after 7 years. For 9\/65 (14%) patients experiencing MRec, recurrence occurred after 2 years in TFR (median, 3.6 years). The residual rate of MRec after 2 years was estimated to be 18%. The probability of remaining in TFR was 65.4% for patients having experienced fluctuations of their minimal residual disease (MRD) (at least 2 consecutive measurements BCR-ABL1IS &amp;gt;0.0032% or loss of MR4), whereas it was 100% for those with stable MRD (P = .003). After 2 years in TFR, we observed an 18% residual rate of LMRec. These late events represent 14% of all MRec and occur in patients with fluctuating MRD measurements. A long-term molecular follow-up therefore remains mandatory for CML patients in TFR. The A-STIM study was registered at www.clinicaltrials.gov as #NCT02897245.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001772","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T15:40:25Z","timestamp":1593704425000},"page":"3034-3040","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3238-4494","authenticated-orcid":false,"given":"Philippe","family":"Rousselot","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Centre Hospitalier de Versailles, Le Chesnay, France;"},{"name":"Unit\u00e9 Mixte de Recherche (UMR) 1184, Institut de Biologie Fran\u00e7ois Jacob, Commissariat \u00e0 l\u00c9nergie Atomique (CEA), University of Versailles-Saint-Quentin-en-Yvelines and Paris-Saclay, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4863-6377","authenticated-orcid":false,"given":"Cl\u00e9mence","family":"Loiseau","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Centre Hospitalier de Versailles, Le Chesnay, France;"},{"name":"Unit\u00e9 Mixte de Recherche (UMR) 1184, Institut de Biologie Fran\u00e7ois Jacob, Commissariat \u00e0 l\u00c9nergie Atomique (CEA), University of Versailles-Saint-Quentin-en-Yvelines and Paris-Saclay, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0455-6749","authenticated-orcid":false,"given":"Marc","family":"Delord","sequence":"first","affiliation":[{"name":"Clinical Research Center, Centre Hospitalier de Versailles, Le Chesnay, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Michel","family":"Cayuela","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and EA3518, University Hospital Saint-Louis Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), University of Paris, Paris, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Spentchian","sequence":"first","affiliation":[{"name":"Department of Molecular Biology, Centre Hospitalier de Versailles, Le Chesnay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"issue":"1","key":"2020070211395717300_B1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2020070211395717300_B2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"2020070211395717300_B3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020070211395717300_B4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2020070211395717300_B5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ajh.23427","article-title":"Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib","volume":"88","author":"Lee","year":"2013","journal-title":"Am J Hematol"},{"issue":"6","key":"2020070211395717300_B6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"97","author":"Takahashi","year":"2012","journal-title":"Haematologica"},{"issue":"21","key":"2020070211395717300_B7","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood.V122.21.654.654","article-title":"Preliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib","volume":"122","author":"Mahon","year":"2013","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"5","key":"2020070211395717300_B8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020070211395717300_B9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"2020070211395717300_B10","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"2020070211395717300_B11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"2020070211395717300_B12","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"12","key":"2020070211395717300_B13","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u201creal-time\u201d quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"issue":"7","key":"2020070211395717300_B14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann Intern Med"},{"issue":"3","key":"2020070211395717300_B15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. [published online ahead of print October 24, 2019]","volume":"61","author":"Shah","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2020070211395717300_B16","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2020070211395717300_B17","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2020070211395717300_B18","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. [published online ahead of print January 21, 2020]","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet Haematol"},{"issue":"22","key":"2020070211395717300_B19","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/cncr.30885","article-title":"Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia","volume":"123","author":"Legros","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"2020070211395717300_B20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2020070211395717300_B21","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"issue":"23","key":"2020070211395717300_B22","doi-asserted-by":"crossref","first-page":"35293","DOI":"10.18632\/oncotarget.9182","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation","volume":"7","author":"Chomel","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"2020070211395717300_B23","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1038\/s41375-018-0264-0","article-title":"Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells","volume":"32","author":"Ross","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"2020070211395717300_B24","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","article-title":"Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy","volume":"107","author":"Kaeda","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2020070211395717300_B25","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2020070211395717300_B26","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"2020070211395717300_B27","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41375-019-0647-x","article-title":"Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. [published online ahead of print November 25, 2019]","volume":"34","author":"Pagani","year":"2020","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/3034\/1747748\/advancesadv2020001772.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/3034\/1747748\/advancesadv2020001772.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T15:40:39Z","timestamp":1593704439000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/13\/3034\/461237\/Late-molecular-recurrences-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001772","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]}}}